Defying the Downturn: Over Six Pharma Companies Secure Over RMB 100 Million in Funding in April

　　【Pharmaceutical Network Industry Dynamics] Currently, although the frequency of investment and financing in the biopharmaceutical industry has declined, some companies have still gained capital favor against the market trend. Since April 2025, companies including iRegene, GeneIII Bio-Tec Co., Ltd, Yellwin, ShineyoMedical, Hangzhou Jirui Technology Co., Ltd, Rishena Medical, and Baojuhe (Suzhou) Medical Technology Co., Ltd have announced successful financing. The participants in these financings include Fengchuan Capital, Rong'an Venture Capital, Taiyu Investment, JAFCO Asia, and Beijing Medical and Health Industry Investment Fund.
 

Specifically, iRegene, a company specializing in universal chemical-induced cell therapy drugs, has recently completed its B+ round of financing. The funds from this round will be used to accelerate the clinical advancement of the company’s Parkinson’s disease treatment products NouvNeu001/NouvNeu003 and ophthalmic treatment product NouvSight001 in both China and the U.S., strengthen the R&D progress of multiple innovative pipelines and the establishment of clinical capabilities, as well as enhance the company’s industrialization efforts.
 

On April 3, Yellwin, a company focused on the research and development of innovative medical devices for cardiac surgery, announced the completion of a multi-million yuan A++ round of financing. This funding will mainly be used to further the development of innovative devices for the full-process treatment of coronary heart disease and new products such as the pulsatile left ventricular assist system, as well as to accelerate the market promotion of already approved products like the heart stabilizer.
 

GeneIII Bio-Tec Co., Ltd., a synthetic biotechnology company, also announced on the 3rd the completion of a Pre-A round of financing worth hundreds of millions. The funds from this round will mainly be used for the upgrading of the ergothioneine raw material production line, the expansion of the end-product portfolio, and the establishment of an international standard certification system.
 

On April 2, Rishena Medical, a company focused on the research and development of implantable medical devices, completed its D-round financing. The funds from this round will be used for R&D investment, enhancing product competitiveness, and promoting market expansion.
 

On the same day, ShineyoMedical, an innovative medical device company, announced that it had successively completed a multi-million yuan A++ round of financing invested by EF Capital and a multi-million yuan A+++ round of financing invested by Baiyun Financial Holdings. The funds from this round of financing will be mainly directed towards the construction of marketing networks, the expansion of industrialization bases, and the layout of innovative R&D pipelines; GeneIII Bio-Tec Co., Ltd. announced that it received additional investment support from the capital under the Anhui Provincial State-owned Assets Supervision and Administration Commission and will increase its asset investment and business layout in China. Data shows that GeneIII Bio-Tec Co., Ltd. is a company focused on the research and development of biological anti-bacterial infection products, primarily utilizing bacteriophages, lysins, and other biological agents combined with related drug delivery technologies to develop products such as antibiotics for drug-resistant bacteria, serving fields like human health, crop health, animal health, and food safety.
 

In addition, Hangzhou Jirui Technology Co., Ltd. announced that it has recently completed two rounds of multi-million financing. The funds from this round of financing will be mainly used for the research and development and iteration of its product, the nuclear medicine molecular imaging tracer automated synthesizer OnePlatform, as well as for the construction of equipment and consumables production lines and the development services of specific tracers. The company is an innovative biopharmaceutical enterprise specializing in the fully automated synthesis platform for nuclear medicine molecular imaging tracers, and the research, production, and sales of radiopharmaceuticals.
 

　　......
 

The development trends of the aforementioned companies after financing have undoubtedly injected new vitality and directions for thought into the industry’s development, also reflecting to a certain extent that the development potential of the biopharmaceuticals sector in niche areas continues to be favored by capital. Industry insiders believe that as a field closely tied to human health, with the intensification of global aging populations, increased market demand in chronic diseases and oncology, and growing emphasis on technological innovation by pharmaceutical and medical device companies, investment firms may become more willing to invest in promising companies.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.